Xencor (XNCR) Accumulated Expenses (2013 - 2026)
Xencor (XNCR) posted quarterly Accumulated Expenses of $34.3 million for Q1 2026, up 113.24% year-over-year from $16.1 million in Q1 2025, and down 2.02% quarter-over-quarter from $35.0 million in Q4 2025.
Analysis
Xencor (XNCR) Accumulated Expenses (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Accumulated Expenses for 14 consecutive years, with $34.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 113.24% year-over-year to $34.3 million; the TTM figure through Mar 2026 stood at $34.3 million (up 113.24% YoY), while the FY2025 annual figure was $35.0 million, up 81.92% from the prior year.
- Accumulated Expenses retreated to $34.3 million in Q1 2026 per XNCR's latest filing, from $35.0 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $35.0 million in Q4 2025 and bottomed at $12.6 million in Q1 2022.
- Historically, Accumulated Expenses has averaged $21.4 million across 5 years, with a median of $19.3 million in 2022.
- Annual changes were most pronounced in 2024 — Accumulated Expenses dropped 18.45% — and 2026, when it jumped 113.24%.
- Xencor's Accumulated Expenses stood at $18.7 million in 2022, then advanced by 25.82% to $23.6 million in 2023, then fell by 18.45% to $19.2 million in 2024, then jumped by 81.92% to $35.0 million in 2025, then declined by 2.02% to $34.3 million in 2026.
- Business Quant data shows XNCR's Accumulated Expenses at $34.3 million in Q1 2026, $35.0 million in Q4 2025, and $28.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.45 Mn |
| Mar 31, 2026 | 34.25 Mn |
| Dec 31, 2025 | 34.96 Mn |
| Sep 30, 2025 | 28.11 Mn |
| Jun 30, 2025 | 23.88 Mn |
| Mar 31, 2025 | 16.06 Mn |
| Dec 31, 2024 | 19.22 Mn |
| Sep 30, 2024 | 25.41 Mn |
| Jun 30, 2024 | 19.56 Mn |
| Mar 31, 2024 | 13.49 Mn |
| Dec 31, 2023 | 23.56 Mn |
| Sep 30, 2023 | 24.47 Mn |
| Jun 30, 2023 | 18.44 Mn |
| Mar 31, 2023 | 15.14 Mn |
| Dec 31, 2022 | 18.73 Mn |
| Sep 30, 2022 | 19.29 Mn |
| Jun 30, 2022 | 16.35 Mn |
| Mar 31, 2022 | 12.61 Mn |
| Dec 31, 2021 | 19.44 Mn |
| Sep 30, 2021 | 22.11 Mn |